Novus Biologicals products are now on bio-techne.com

CD19

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy

How To Identify B Cell Subsets Using Flow Cytometry

Antigen-loss relapse after successful CAR-T therapy; What do we do now?

Acute lymphoblastic leukemia disease bioinformatics

By Jacqueline Carrico, BS, MD

Article Review: Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer

The immune system is composed of a portion of T cells that express an invariant T cell receptor (TCR) alpha chain known as V alpha 24 J alpha 18. These highly conserved populations are referred to as iNKT populations and have the ability to rapidly produce cytokines following activation, making them hot targets for therapeutic research initiatives.

CD19: An Undoubted Biomarker for B Cells

CD19 is a cell surface protein member of the large immunoglobulin superfamily that complexes with CD21, CD81, and CD225 in the membrane of mature B-cells. A major function of CD19 is to assemble with the antigen receptor of B-lymphocytes to decrease the threshold for receptor-dependent stimulation, thus enhancing the specificity and sensitivity of B-cells towards antigens. CD19 plays a large role in regulating B-cell growth.